Table 5.
Mode of detection and subsequent breast cancer mortality in relation to breast density
| Rate of breast cancer deaths | HR 1 | HR 2 | HR 3 | HR 4 | |
|---|---|---|---|---|---|
|
All |
|
|
|
|
|
| Non-symptomatic |
27 of 350 |
1.00 |
1.00 |
1.00 |
1.00 |
| Symptomatic |
49 of 269 |
2.68 (1.67-4.28) |
1.55 (0.95-2.53) |
1.52 (0.92-2.50) |
1.56 (0.94-2.58) |
|
Freedmans%* |
|
|
55.5 |
57.5 |
54.9 |
|
Fatty/moderate |
|
|
|
|
|
| Non-symptomatic |
16 of 233 |
1.00 |
1.00 |
1.00 |
– |
| Symptomatic |
28 of 172 |
2.63 (1.42-4.87) |
1.48 (0.76-2.88) |
1.54 (0.79-3.02) |
– |
|
Dense |
|
|
|
|
|
| Non-symptomatic |
11 of 117 |
1.00 |
1.00 |
1.00 |
– |
| Symptomatic | 21 of 97 | 2.63 (1.26-5.47) | 1.71 (0.75-3.90) | 1.63 (0.68-3.91) | – |
HR1: Crude.
HR2: Adjusted for diagnostic age (continuous), tumour size (mm), ALNI, grade, ER, PgR and diagnostic period.
HR3 Adjusted for same factors as HR2 but also for BMI at baseline (continuous), HRT at diagnosis and diagnostic period.
HR4: Adjusted for the same factors as HR3 but also for breast density.
*Freedmans% express to what extent covariates can explain the differences in mortality between non-symptomatic vs. symptomatic patients.